ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and therapy"

  • Abstract Number: 569 • 2018 ACR/ARHP Annual Meeting

    Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry

    Joel Kremer1,2, J. Lynn Palmer3, George W. Reed4, Dimitrios A. Pappas5, Leslie R Harrold6, Jeffrey Greenberg1 and Jeffrey R. Curtis7, 1Corrona LLC, Waltham, MA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Corrona Research Foundation, Albany, NY, 4UMass Medical School, Worcester, MA, 5Columbia University, New York, NY, 6University of Massachusetts Medical School, Worcester, MA, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The combination of methotrexate (MTX), hydroxychloroquine (HCQ) and sulfasalazine (SSZ) has been called Triple Therapy (Triple) and has been compared with a combination of…
  • Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting

    Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab

    Christof Specker1, Annette Alberding2, Martin Aringer3, Gerd R. Burmester4, Jan-Paul Flacke5, Michael Hofmann6, Peter Kaestner7, Herbert Kellner8, Frank Moosig9, Maren Sieburg10, Hans-Peter Tony11 and Gerhard Fliedner12, 1Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, 2Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, 3Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 4Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 5Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, 6Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, 7Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, 8Ambulantes Rheumazentrum, Erfurt, Germany, 9Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, 10Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, 11Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, 12Rheumatological Practice, Osnabrueck, Germany

    Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
  • Abstract Number: 2432 • 2018 ACR/ARHP Annual Meeting

    Peripartum Issues in the Inflammatory Arthritis (IA) Patient: A Survey of the Rapport (Rheumatoid Arthritis Pharmacovigilence Program and Outcomes Research in New Therapies) Registry

    Tharindri Dissanayake1, Stephanie Keeling2 and Walter P. Maksymowych3, 1Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, 2Department of Medicine, University of Alberta, University of Alberta, Edmonton, AB, Canada, 3CaRE Arthritis, Edmonton, AB, Canada

    Background/Purpose: Multiple issues surround the peripartum period for IA patients including medication use, risk of disease flare and potential impact on neonatal outcomes. We aimed…
  • Abstract Number: 2528 • 2018 ACR/ARHP Annual Meeting

    A Multicenter Study Assessing the Efficacy and Safety of Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: Preliminary Interim Data from the Open-Label Treatment Period

    Roy Fleischmann1, Daniel E. Furst2, Richard Brasington3, Erin Connolly-Strong4, Jingyu Liu4 and Matthew E. Barton4, 1University of Texas Southwestern Medical Center, Dallas, TX, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Washington University School of Medicine, St. Louis, MO, 4Mallinckrodt ARD, Inc., Bedminster, NJ

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder associated with chronic inflammation and commonly treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. Repository corticotropin injection…
  • Abstract Number: 2536 • 2018 ACR/ARHP Annual Meeting

    Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy

    Frieda A. Koopman1, Anne Musters2, Marieke M.J. Backer2, Danielle Gerlag2, Sanda Miljko3, Simeon Grazio4, Sekib Sokolovic5, Yaakov Levine6, David Chernoff6, Niek de Vries7 and Paul-Peter Tak2, 1Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3University Clinical Hospital, Mostar, Bosnia, 4Vinogradsira 29, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, 5Rheumatology, Sarajevo University Clinical Center, Sarajevo, BA, 6SetPoint Medical, Inc., Valencia, CA, 7Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: RA is a debilitating chronic disease with an unmet need for additional therapeutic approaches. Modulating innate neuro-immune reflex pathways by stimulation of the vagus…
  • Abstract Number: 2483 • 2017 ACR/ARHP Annual Meeting

    Cycling Versus Swapping in Patients with Rheumatoid Arthritis with an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor: A Systematic Review and Meta-Analysis of Observational Studies

    Maria A. Lopez-Olivo, Aliza Matusevich and Maria Suarez-Almazor, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX

    Background/Purpose: In patients with rheumatoid arthritis (RA) who do not respond or lose response to a tumor necrosis factor inhibitor (TNFi), opinions are divided on…
  • Abstract Number: 529 • 2017 ACR/ARHP Annual Meeting

    Pulmonary Involvement in Our Patients with Rheumatoid Arthritis Under Biological Therapy: A Tertiary Hospital Experience

    Edurne Guerrero Basterretxea1, Maria Luz Garcia Vivar1, Itziar Calvo Zorrilla1, Oihane Ibarguengoitia2, Eva Galíndez Agirregoikoa2, Juan Maria Blanco Madrigal3, Esther Ruíz Lucea1, Ignacio Torre Salaberri1, Olaia Begoña Fernandez Berrizbeitia2, Clara Eugenia Perez1, Ana Rosa Intxaurbe Pellejero2, Natalia Rivera-García4 and Iñigo Gorostiza Hormaetxe5, 1RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 2RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, BILBAO, Spain, 3Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 4RESEARCH, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 5RESEARCH, Research Department. Basurto University Hospital, BILBAO, Spain

    Background/Purpose: Use of biological therapy (BT) has dramatically improved Rheumatoid Arthritis (RA) management and outcomes for the last decade. Classic extraarticular manifestations are now uncommon,…
  • Abstract Number: 1302 • 2016 ACR/ARHP Annual Meeting

    Silent Progression in Patients with Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results from the German Remission-PLUS Cohort

    Dr. Philipp Sewerin1, PD Dr. Stefan Vordenbäumen1, Annika Hoyer2, Ralph Brinks1, Dr. Christian Buchbender3, Dr. Christoph Schleich4, Sabine Kamp1, Prof. Dr. Gerald Antoch3, Prof. Dr. Matthias Schneider1 and Prof. Dr. Benedikt Ostendorf1, 1Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany, 2Institute for Biometry and Epidemiology, German Diabetes Center, Duesseldorf, Germany, 3Diagnostic and Interventional Radiology, Heinrich-Heine-University, Düsseldorf, Germany, 4Dep. for diagnostic and interventional Radiology, Heinrich-Heine-University, Duesseldorf, Germany

    Background/Purpose: disease activity score in 28 joints; Methods: Data-sets of 80 RA patients from the REMISSION-plus study cohort who fulfilled the following criteria were retrospectively…
  • Abstract Number: 1306 • 2016 ACR/ARHP Annual Meeting

    Magnetic Resonance Imaging Measures of Disease Activity in Rheumatoid Arthritis Patients Treated with Multiple Regimens of DMARD Therapy

    Paolo Pace1, Arthur Lau2, Jonathan D. Adachi3, Matthew A. Jessome4, George Ioannidis2 and Minta Patel5, 1Rheumatology, McMaster Unversity, Hamilton, ON, Canada, 2St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 3McMaster University, Hamilton, ON, Canada, 4Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, 5Cambridge Memorial Hospital, Cambridge, ON, Canada

    Background/Purpose: Magnetic resonance imaging ( MRI ) in rheumatoid arthritis ( RA ) has been shown to be more sensitive than clinical and radiological parameters…
  • Abstract Number: 1418 • 2016 ACR/ARHP Annual Meeting

    Rheumatologist: If You Fell Ill with Seropositive Active Rheumatoid Arthritis Yourself, What to Do!

    Kalle Aaltonen1, Elena Nikiphorou2,3, Nasim A. Khan4 and Tuulikki Sokka5, 1Helsinki University, Helsinki, Finland, 2Whittington Hospital, London, United Kingdom, 3Jyväskylä Central Hospital, Jyväskylä, Finland, 4Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, 5Jyvaskyla Central Hospital, Jyväskylä, Finland

    Background/Purpose: International and national bodies have given evidence-based recommendations for rheumatoid arthritis (RA) treatment. We assessed the general uptake of these recommendations by asking rheumatologists…
  • Abstract Number: 2512 • 2016 ACR/ARHP Annual Meeting

    Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden

    Jon T. Einarsson1, Minna Willim1, Sofia Ernestam2, Tore Saxne1, Pierre Geborek1 and Meliha C. Kapetanovic1, 1Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, 2Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden

      Background/Purpose: Remission has become a treatment goal in rheumatoid arthritis (RA) especially after the introduction of biologic treatment in 1999. The Swedish quality registry…
  • Abstract Number: 3068 • 2016 ACR/ARHP Annual Meeting

    Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA

    Susan J. Bartlett1,2, Orit Schieir3, Kathleen Andersen4, Gilles Boire5, Boulos Haraoui6, Carol Hitchon7, Edward Keystone8, Janet E. Pope9, J Carter Thorne10, Diane Tin11, Vivian P. Bykerk12 and Canadian Early Arthritis Cohort (CATCH) Investigators, 1Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Toronto, Toronto, ON, Canada, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 61551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, 9University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 12Divison of Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Early, aggressive treatment to achieve remission is the primary goal when treating early RA, and is associated with improved long-term outcomes. We have previously…
  • Abstract Number: 28 • 2015 ACR/ARHP Annual Meeting

    The Decrease over Time of Orthopaedic Surgery in Patients with Rheumatoid Arthritis Is Mainly Due to Reduced Rates Among Those with Rheumatoid Factor Positive Disease – Results from a Well Defined Area

    Korosh Hekmat1,2, Lennart T.H. Jacobsson3, Jan-Åke Nilsson1, Minna Willim1, Martin Englund4,5, Ingemar F Petersson4 and Carl Turesson6, 1Department of Rheumatology. Malmö University Hospital, Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Karolinska University Hospital, Department of Medicine, Unit of Rheumatology, Stockholm, Stockholm, Sweden, 3Department of Rheumatology Malmö University Hospital, Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 5Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose : Seropositive and seronegative rheumatoid arthritis (RA) differ in course and prognostic feature. The overall incidence of orthopaedic surgery in patients with RA has…
  • Abstract Number: 449 • 2015 ACR/ARHP Annual Meeting

    Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)

    Ruediger Mueller1, Michael Gengenbacher2, Symi richter3, Jean Dudler4, Burkhard Moeller5 and Johannes von Kempis6, 1Rheumatology, MD, St. Gallen, Switzerland, 2Bethesdaspital, Basel, Switzerland, 3Bethsdaspital, Basel, Switzerland, 4Kantonsspital Fribourg, Fribourg, Switzerland, 5Rheumatology, Inselspital-University Hospital, Bern, Switzerland, 6Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Background/Purpose: Holiday seasons can present a major problem to RA patients treated with weekly subcutaneous biologics, including subcutaneous (SC) abatacept. Therefore an evaluation of the…
  • Abstract Number: 457 • 2015 ACR/ARHP Annual Meeting

    RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics

    Marcia S. Genta1, Amnon Sonnenberg2 and Robert M. Genta3, 1Dallas Arthritis Center, Dallas, TX, 2Medicine - Gastroenterology, Portland VAMC - Oregon Health & Science University, Portland, OR, 3Laboratory, Dallas Arthritis Center, Dallas, TX

    Background/Purpose: We have previously shown that patients with Medicare only coverage without financial assistance from foundations were significantly less likely to receive Biologics than patients…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology